| Literature DB >> 35518523 |
Hamza Islam1, Sri Madhurima Puttagunta2, Rabia Islam1, Sumana Kundu3, Surajkumar B Jha4, Ana P Rivera5, Gabriela Vanessa Flores Monar6, Ibrahim Sange7.
Abstract
Mitral stenosis (MS), a valvular heart disease, is defined by the narrowing of the mitral valve orifice. The common risk factors for stroke include mitral annular calcification (MAC), diabetes mellitus (DM), male gender, hypertension (HTN), hyperlipidemia, and obesity. Endothelial damage, hypercoagulability, and blood stasis in the left atrium promote the development of the thrombus. Among all the risk factors described, MAC is the independent predictor of stroke. The complicated mechanisms responsible for thromboembolism, predisposing factors for thromboembolism, the risk of cerebrovascular accident (CVA) in MS patients, advanced standardized assessment models for identifying those at risk for stroke, and the possible advantages and disadvantages of available therapies have all been discussed in this review article. We have also discussed newer oral anticoagulants (NOACs) like dabigatran, edoxaban, apixaban, and rivaroxaban. Non-pharmacological therapies are also highlighted such as left atrial appendage ligation and occlusion devices. We also conducted a thorough review of the literature on the efficacy and safety of various NOACs in reducing the risk of stroke.Entities:
Keywords: apixaban and edoxaban; cerebrovascular accident (stroke); cha2ds2-vasc; left atrial thrombus; mitral annular calcification; mitral valve stenosis; newer oral anticoagulants; thromboembolism; vitamin k antagonists (vkas); watchman device
Year: 2022 PMID: 35518523 PMCID: PMC9063730 DOI: 10.7759/cureus.23784
Source DB: PubMed Journal: Cureus ISSN: 2168-8184